Intraperitoneal Perfusion Therapy of Endostar Combined with Platinum Chemotherapy for Malignant Serous Effusions: A Meta-analysis

Liang, Rong; Xie, Hai-Ying; Lin, Yan; Li, Qian; Yuan, Chun-Ling; Liu, Zhi-Hui; Li, Yong-Qiang

추천

검색

자료유형: 학술저널

저자정보: Liang, Rong (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) Xie, Hai-Ying (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) Lin, Yan (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) Li, Qian (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) Yuan, Chun-Ling (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) Liu, Zhi-Hui (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University) Li, Yong-Qiang (Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제18호

발행연도: 2015.1

수록면: 8,637 - 8,644 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Malignant serous effusions (MSE) are one complication in patients with advanced cancer. Endostar is a new anti-tumor drug targeting vessels which exerts potent inhibition of neovascularization. This study aimed to systematically evaluate the efficacy and safety of intraperitoneal perfusion therapy of Endostar combined with platinum chemotherapy for malignant serous effusions (MSE). Materials and Methods: Randomized controlled trials (RCTs) on intraperitoneal perfusion therapy of Endostar combined with platinum chemotherapy for malignant serous effusions were searched in the electronic data of PubMed, EMBASE, Web of Science, CNKI, VIP, CBM and WanFang. The quality of RCTs was evaluated by two independent researchers and a meta-analysis was performed using RevMan 5.3 software. Results: The total of 25 RCTs included in the meta-analysis covered 1,253 patients, and all literature quality was evaluated as "B" grade. The meta-analysis showed that Endostar combined with platinum had an advantage over platinum alone in terms of response rate of effusions (76% vs 48%, RR=1.63, 95%CI: 1.50-1.78, P<0.00001) and improvement rate in quality of life (69% vs 44%, RR=1.57, 95%CI: 1.42-1.74, P<0.00001). As for safety, there was no significant difference between the two groups in the incidences of nausea and vomiting (35% vs 34%, RR=1.01, 95%CI: 0.87-1.18, P=0.88), leucopenia (38% vs 38%, RR=1, 95%CI: 0.87-1.15, P=0.99), and renal impairment (18% vs 20%, RR=0.86, 95%CI: 0.43-1.74, P=0.68). Conclusions: Endostar combined with platinum by intraperitoneal perfusion is effective for malignant serous effusions, and patient quality of life is significantly improved without the incidence of adverse reactions being obviously increased.

#Endostar #malignant serous effusions #meta-analysis #randomized controlled trials

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!